Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Azacitidine plus R-GemOx for relapsed/refractory DLBCL (single-arm, phase 4)
ChiCTR2400093023Phase 4Not yet recruiting
- Sponsor
- Army Specialized Medical Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of azacitidine, rituximab, gemcitabine and oxaliplatin in diffuse large B-cell lymphoma (DLBCL), sponsored by Army Specialized Medical Center. Primary endpoints: Overall response rate and Overall survival. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
azacitidinerituximabgemcitabineoxaliplatin
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on ChiCTR2400093023.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400093023.